Skip to main content

Table 2 Baseline characteristics and changes in parameters after 12 weeks of treatment

From: Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study

 

Placebo (n = 25)

Empa (n = 26)

Difference between groups

Baseline

Posttreatment

p

Baseline

Posttreatment

p

p

Clinical parameters

 Systolic blood pressure (mm Hg)

124 ± 16

124 ± 13

0.9395

125 ± 9

124 ± 9

0.5717

0.7109

 Diastolic blood pressure (mm Hg)

74 ± 11

73 ± 10

0.8425

71 ± 8

71 ± 10

0.9717

0.9063

 Weight (kg)

93 [83;105]

94 [82;104]

0.8882

91 [81;105]

89 [80;102]

 < 0.0001

0.0047

 BMI (kg/m2)

34.1 [30.4;39.5]

33.2 [30.3;38.3]

0.8851

32.6 [31.8;36.5]

32 [30.6;35.3]

 < 0.0001

0.0045

 Waist circumference (cm)

113 [103;124]

112 [102;121]

0.2623

114 [103;120]

113 [101;117]

0.0360

0.4266

Biological parameters

 Fasting blood glucose (mmol/L)

9.22 ± 2.49

8.74 ± 2.42

0.2516

9.59 ± 2.44

7.35 ± 1.73

 < 0.0001

0.0063

 HbA1c (%)

8.1 ± 1.1

7.8 ± 0.9

0.0605

8.1 ± 1.0

7.3 ± 0.6

 < 0.0001

0.0033

 Total cholesterol (g/L)

1.72 ± 0.40

1.68 ± 0.35

0.5340

1.57 ± 0.37

1.57 ± 0.44

0.8655

0.5111

 HDL-cholesterol (g/L)

0.41 [0.32;0.45]

0.42 [0.33;0.5]

0.7394

0.40 [0.36;0.50]

0.46 [0.38;0.53]

0.0123

0.1359

 LDL-cholesterol (g/L)

0.92 ± 0.25

0.92 ± 0.29

0.9668

0.83 ± 0.30

0.84 ± 0.34

0.6199

0.7940

 Triglycerides (g/L)

1.56 [1.11;2.13]

1.47 [1.01;2.35]

0.9881

1.48 [0.94;1.97]

1.27 [0.84;1.54]

0.0451

0.6447

 Uricemia (µmol/L)

284.6 ± 81.1

296.0 ± 87.8

0.3391

301.8 ± 82.3

265.7 ± 67.1

0.0052

0.0062

 Ferritinemia

65.0 [15.0;158.9]

60.2 [16.4;126.5]

0.8462

75.7 [34.3;133.0]

48.6 [19.9;92.3]

 < 0.0001

0.0445

 hs-CRP (mg/L)

3.7 [1.8;5.1]

3.4 [1.7;6.1]

0.1058

2.3 [1.0;5.6]

2.3 [1;5.3]

0.1349

0.2044

 PAI-1 (UI/L)

41 [11;79]

36.5 [10.2;72]

0.3938

24 [15.2;39.2]

16 [8.5;28.5]

0.1396

0.4318

 AST (UI/L)

23 [20;32]

24 [18;33]

0.6062

23 [20;33]

23 [19;32]

0.2339

0.1219

 ALT (UI/L)

33 [23;54]

34 [23;44]

0.3178

30 [25;42]

28 [18;44]

0.0302

0.0705

 GGT (UI/L)

42 [30;76]

43 [26;63]

0.3698

36 [26;47]

28 [24;42]

0.0002

0.2219

 Hematocrit

0.38 [0.35;0.41]

0.38 [0.36;0.43]

0.5520

0.40 [0.37;0.43]

0.43 [0.40;0.46]

 < 0.0001

0.0001

 Reticulocytes (%)

1.4 [1.2;1.8]

1.5 [1.1;1.7]

0.4463

1.5 [1.2;1.8]

1.3 [1.2;1.6]

0.0030

0.0027

 EPO (mU/mL)

13 [8.5;18]

11 [8.2;16.5]

0.1709

8.7 [4.9;14]

9.2 [5.9;13.7]

0.1789

0.0412

 Glycosuria (mmol/L)

0.75 [0.31;3.13]

1.06 [0.36;5.72]

0.6434

1.13 [0.56;12.83]

193.3 [125.4;256.7]

 < 0.0001

 < 0.0001

MRI parameters

 Ejection fraction (%)

63.7 ± 8.3

63.3 ± 7.7

0.6598

63.1 ± 8.2

63.3 ± 7.2

0.8515

0.6515

 LVM (g)

129 [107;149]

124 [107;151]

0.2217

117 [93;150]

110 [97;142]

0.5153

0.9707

 LVMi (g)

64 [59;72]

64 [57;69]

0.1429

58 [51;66]

58 [52;64]

0.3802

0.9545

 E/A ratio

1.26 [1.07;1.49]

1.17 [0.85;1.44]

0.3289

1.14 [0.90;1.71]

1.08 [0.92;1.62]

0.5619

0.3923

  1. BMI body mass index; PAI-1 plasminogen activator inhibitor-1; EPO: erythropoietin; LVEF left ventricular ejection fraction; LVM left ventricular mass; LVMi left ventricular mass indexed to body surface area
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840